Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Gillian K. Gresham

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7142-1230; OpenAlex author ID A5081040315. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
1
Labs led
0
Collaborators
26
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper, 1 trial, 1 grant · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. Correction: Chang et al. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Cancers 2025, 17, 630. Co-author DOI 10.3390/cancers18050789↗
  2. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  3. Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model. Co-author DOI 10.3390/cancers17040630↗
  4. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-19401-3↗
  5. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-23619-6↗
  6. Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.12799↗
  7. Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives. First author DOI 10.6004/jnccn.2020.7548↗
  8. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. Co-author DOI 10.1186/1471-2407-14-471↗

Trials 1

  1. Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients Principal investigator NCT04604158↗

Grants 1

  1. Evaluating Objective Measures of Physical Function in Pancreatic Cancer AWARD pancan:2020-gillian-gresham-phd-evaluating-objective-measures-of-physica

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 7 shared papers, 2020–2026 · strength 1.32
  2. Jun Gong · 5 shared papers, 2020–2025 · strength 0.70
  3. An Ngo‐Huang · 2 shared papers, 2025–2026 · strength 0.62
  4. Nathan H. Parker · 2 shared papers, 2025–2026 · strength 0.62
  5. Andrew L. Coveler · 2 shared papers, 2025–2026 · strength 0.62
  6. Philip J. Chang · 2 shared papers, 2025–2026 · strength 0.62
  7. Paul E. Oberstein · 2 shared papers, 2025–2026 · strength 0.62
  8. Arsen Osipov · 4 shared papers, 2021–2025 · strength 0.58
  9. Simon K. Lo · 3 shared papers, 2021–2022 · strength 0.38
  10. Natalie Moshayedi · 2 shared papers, 2022 · strength 0.27
  11. Srinivas Gaddam · 2 shared papers, 2022 · strength 0.27
  12. Veronica Placencio-Hickok · 2 shared papers, 2020–2021 · strength 0.23
  13. Rachna T. Shroff · 1 shared paper, 2025 · strength 0.20
  14. Matthew Ebia · 1 shared paper, 2025 · strength 0.20
  15. Emanuel F. Petricoin · 1 shared paper, 2025 · strength 0.20
  16. Jennifer W. Chuy · 1 shared paper, 2025 · strength 0.20
  17. Raymond Couric Wadlow · 1 shared paper, 2025 · strength 0.20
  18. Lei Zheng · 1 shared paper, 2025 · strength 0.20
  19. Abrahm Levi · 1 shared paper, 2025 · strength 0.20
  20. Michael Jon Pishvaian · 1 shared paper, 2025 · strength 0.20
  21. Lynn McCormick Matrisian · 1 shared paper, 2025 · strength 0.20
  22. Michelle Guan · 1 shared paper, 2020 · strength 0.12
  23. Nicholas N. Nissen · 1 shared paper, 2021 · strength 0.11
  24. Stephen Jacob Pandol · 1 shared paper, 2021 · strength 0.11
  25. Sharlene Gill · 1 shared paper, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.